Respiratory disorders are diseases that primarily affect the overall health of the lungs and the entire respiratory system. Respiratory disorders, such as asthma, COPD, ARDS, and fibrosis result in breathing problems. Generally, these are caused by air pollution, infection, smoking, asbestos, radon, and other factors.
Unfortunately, the world people live in today isn’t exactly the safest for those with respiratory illnesses. Pollution and exposure to toxic substances continue to contribute to the rising number of patients that are diagnosed with respiratory diseases. These individuals are those that could be as young as infants, and as vulnerable as the senior citizens. As such, the value of the global respiratory inhaler devices market is expected to reach $43,214 million by 2025 end and it’s estimated to witness 4.3% CAGR during the forecast period, 2025, according to the report by (RRI).
Thanks to technology, there are now many ways to manage respiratory disease. In fact, many of these patients can now live longer lives when they’ve got access to the latest respiratory devices, which are used for assisting patients encountering such breathing problems. Doctors in this field, more specifically referred to as a pulmonologist, are also seeing brighter days for their patients because of these sophisticated treatment forms.
Global Respiratory Inhaler Devices Market Estimated to Witness 4.3% CAGR By End 2025
These inhaler devices are also those that are most commonly prescribed for maintenance medication of patients suffering from respiratory diseases.
Major players in the global respiratory inhaler devices market are focusing on the enhancement of their product portfolio by introducing cost-effective and innovative products for strengthening their market position for future advancements. These major players include Beximco Pharmaceuticals Ltd., Cipla Ltd., Koninklijke Philips N.V., PARI Medical Holding, AstraZeneca, Boehringer Ingelheim GmBH, GlaxoSmithKline plc, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., and OMRON Healthcare Europe B.V.
Combination Therapy Estimated to Gain Traction During the Forecast Period
Increasing prevalence of asthma, COPD, chronic respiratory diseases and several other respiratory diseases are driving the growth of the global market for respiratory inhaler devices. Patients are inclining towards combined therapies owing to associated benefits like significant reliability in complex patients, easy reimbursement policies of therapy, and increased efficacy.
It’s worth noting that combination therapies are costlier than conventional therapies. However, combination therapy is likely to gain traction during the forecast period owing to increased utilization of combination therapies for COPD patients. Further, a single effective inhaler for the treatment of all types of respiratory diseases has not yet been discovered. This factor is restraining the growth of the global respiratory inhaler devices market.
Other impeding factors include drug-related complications and side effects, lack of skilled physicians, nurses, pulmonologists, unawareness, and high costs of inhaler devices.
COPD Segment Expected to Witness 4.8% CAGR During 2015 to 2025
Based on disease indication, the market is categorized into asthma, pulmonary arterial hypertension, COPD, and other respiratory diseases. COPD is estimated to be the third largest cause of death and the fifth largest cause of disability from 2015 to 2020.
Several health programs conducted around the world are expected to result in COPD segment. This segment is anticipated to witness 4.8% CAGR during the forecast period.
Application of Bluetooth and GPS Fuelling Demand for Digitally Operated Inhalers
Based on technology, the market is bifurcated into manually operated and digitally operated inhaler devices. The application of Bluetooth and GPS in inhaler devices is anticipated to fuel demand for digitally operated inhaler devices during the forecast period.
This segment is estimated to witness 3.8% CAGR from 2015 to 2025.
Pulmonary Artery Catheter Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025
Another one of the respiratory devices that should be discussed is the pulmonary artery catheter. This catheter is inserted into the pulmonary artery of the heart to aid in the carrying and transfer of blood from the right ventricle of the heart to the lungs for purification.
This is seen also to rise in demand since it’s now used not just in post-operative treatment, but also for patients that are suffering from lifestyle disorders. Generally, the major market for these devices is those coming from The USA and Canada, mostly due to sedentary lifestyles. The Middle East and Africa are the least users but may be seen as an emerging market due to lifestyle changes.
The devices enumerated above are only a few of those that are of use today in the treatment of respiratory diseases. As technology continues to improve, it’s expected that these technologies will also improve in function as well.
While the general goal is to have lesser dependence on these devices, as it would mean that people are now healthy, unfortunately, statistics show otherwise. The good news is that for those that need it, there are now devices, like those enumerated above, to help respiratory patients live happier and more normal lives.
Source: Click here